Product Images Pregabalin

This is a description of Pregabalin capsules, each containing 75 mg of USP. The drug should be kept out of the reach of children and stored at room temperature of 20°-25°C (68°-77°F). The product is manufactured by H BRP Pharmaceuticals and packaged in 30 capsules. The NDC number for the product is 71335-1476-01.*

This text appears to be a prescription label for a medication called "Pachaged" (possible error because of the unusual name) prepared by Bryant Ranck Prepack. The label is recommending to compare it with Lyrica, a medication used for nerve pain. The pack contains 30 capsules and has an expiration date mentioned. The NDC number of the medication is 7133514761. The label recommends storing medicines at room temperature, and keeping them out of reach of children.*

The text describes a table showing the percentage of patients who improved after taking Pregabalin 160mg for three days. The table also displays numerical values for improvement in pain from a baseline. No further context or information is available.*

The text appears to be a chart or data table with some numbers and drug names mentioned. It is not possible to generate a useful description with this information only.*

This appears to be a table showing different doses of Pregabalin and a placebo in a study on pain improvement. The table shows the daily doses of Pregabalin at 450mg and 100mg, as well as a placebo. The last row appears to indicate the percentage of patients who reported a certain level of improvement in pain compared to their baseline. Overall, this table suggests that Pregabalin may be effective in reducing pain, but further context is needed to fully understand the study.*

This text seems to show some data related to the estimated percentage of subjects without LTR, under the effect of Pregabalin and placebo for a certain number of days. However, the context and purpose are not clear.*

This appears to be a table or graph showing the percentage of improvement in subjects who took pregabalin versus those who took a placebo, with the time frame being from baseline to week 16. The numbers on the x-axis range from 210 to 270, with corresponding percentages of improvement on the y-axis. The percentage of subjects who improved while taking pregabalin appears to be consistently higher than those who took the placebo. However, it is unclear what the study or condition being analyzed is without further context.*